Johnson & Johnson (JNJ) closed at $285.75 on November 13, 2026, up 0.8% from the previous close, on volume of 5,326,721 shares (30-day average 7,771,074).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Put Spread | 30-Oct-26255 : 260 P | 21,820 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Mon, 16-Nov 8:00 AM ET)
M&A News: Johnson & Johnson Has $3.4B Eye Biotech Ollin Biosciences in Its Sights
TipRanks (Mon, 16-Nov 6:54 AM ET)
J&J in discussions to buy Ollin Biosciences for up to $3.4B - report
Seeking Alpha News (Mon, 16-Nov 12:21 AM ET)
U.S. Stocks Finish in the Red as the AI Trade Falters
TipRanks (Fri, 13-Nov 4:03 PM ET)
TipRanks (Thu, 12-Nov 6:30 AM ET)
TipRanks (Thu, 12-Nov 6:15 AM ET)
Democratic senators probe gifts to RFK Jr. from large donor to his presidential campaign
Seeking Alpha News (Wed, 11-Nov 3:39 PM ET)
Halozyme downgraded at Morgan Stanley on valuation
Seeking Alpha News (Wed, 11-Nov 12:09 PM ET)
Globe Newswire (Tue, 10-Nov 6:35 PM ET)
PRNewswire (Tue, 10-Nov 8:01 AM ET)
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.
As of November 13, 2026, JNJ stock price climbed to $285.75 with 5,326,721 million shares trading.
JNJ has a beta of -0.42, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.05 to the broad based SPY ETF.
JNJ has a market cap of $688.09 billion. This is considered a Mega Cap stock.
Last quarter Johnson & Johnson reported $25 billion in Revenue and $2.59 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.06.
In the last 3 years, JNJ traded as high as $288.11 and as low as $140.68.
The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
JNJ has outperformed the market in the last year with a price return of +49.1% while the SPY ETF gained +13.4%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.5% and +4.6%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
JNJ support price is $278.32 and resistance is $288.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.